All posts by: Michael Zand

About Michael Zand

Karmanos Cancer Institute offers new cellular therapy for lymphoma – Southgate News Herald

Continue reading

2018-04-18 NEWS

Karmanos Cancer Institute offers new cellular therapy for lymphoma
Southgate News Herald
CAR-T chimeric antigen receptor T cell therapy — is new a type of immunotherapy — born out of years of cellular therapy research. The Michigan doctors working in this new field are Joseph Uberti, Karmanos’ division chief of hematology and co-director

and more »

Continue reading

2018-04-18 NEWS

Karmanos Cancer Institute offers new cellular therapy for lymphoma
Southgate News Herald
CAR-T chimeric antigen receptor T cell therapy — is new a type of immunotherapy — born out of years of cellular therapy research. The Michigan doctors working in this new field are Joseph Uberti, Karmanos’ division chief of hematology and co-director

and more »

Continue reading

2018-04-18 NEWS

Karmanos Cancer Institute offers new cellular therapy for lymphoma
Dearborn Press and Guide
CAR-T chimeric antigen receptor T cell therapy — is new a type of immunotherapy — born out of years of cellular therapy research. The Michigan doctors working in this new field are Joseph Uberti, Karmanos’ division chief of hematology and co-director

and more »

Continue reading

2018-04-18 NEWS

Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
PMLiVE
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the challenges that come with developing products in this complex market